

Paper ET19

From Specification to CSR -- Toward a Unified Analysis and Review Platform

Steve Ross, Beaconcure, Raleigh NC, USA

Achinoam Ravet Perel, Beaconcure, Boston, MA, USA

ABSTRACT

Over years filled with increasingly complex clinical trials, 'bigger data', and increased regulatory burden, the requirements associated with TLF development and review have similarly ballooned into a collection of disconnected, redundant, and inefficient processes. The working space between TLF shell design and final displays is a distinct group of highly specific tasks requiring a high level of communication and collaboration to achieve a high-quality and error-free product. The current 'Gold Standard' process -- double programming plus extensive manual review, is ripe for reimagination.


In today's IT landscape, unified SaaS platforms enhance efficiency, reduce manual effort, and streamline processes. This paper discusses where process efficiency can be gained by rebalancing the efforts of man and machine, where AI fits into a specialized process model that does not lend itself to off-the-shelf solutions, and how technology can address the often disjointed current systems for communication and information management.

INTRODUCTION


Clinical trial complexity has grown exponentially over the past decade, driven by adaptive trial designs, larger, more complex and varied datasets, and increasingly stringent regulatory requirements. The traditional "Gold Standard" approach to TLF (tables, listings, and figures) development—relying on double programming and extensive manual review—while effective, has become increasingly resource-intensive and time-consuming. This paper examines key challenges in current TLF development processes and proposes solutions via a comprehensive analysis and review platform (Verify) that unifies teams and converts manual review tasks to automated AI-driven solutions.

CURRENT LANDSCAPE AND PAIN POINTS

The development and review of clinical trial summary tables, listings, and figures face several critical challenges that impact both efficiency and quality. **Communication fragmentation** arises from the utilization of a complex web of communication channels ranging from in-person meetings, direct messaging through platforms like Teams and Slack, voice calls, multiple QC trackers, email chains with varied distribution lists, and marked-up PDFs. This fragmentation inevitably leads to fragmented messaging, lost or overlooked information, significant difficulties in tracking and documenting decision histories, and extends review cycles unnecessarily.



Similarly, the traditional TLF development workflow is further interrupted by **collaboration silos** that disrupt and discourage efficient information transfer. These silos are designed breaks between functional groups (Statistics and programming, internal and external SMEs) and manifest in sequential, duplicative reviews of study documents and TLFs, with full collaboration limited to functional groups. Transference of key study information is dependent on manual processes, such as copying and pasting of comments/resolutions from spreadsheet to spreadsheet, and the forwarding of emails by parties to the conversation.




Finally, the traditional TLF development cycle relies on multiple built-in **iterative layers of review and validation** that encourage inefficiency. Production and validation programmers work in parallel, while both internal review teams (comprising statisticians, project managers, pharmacokinetic specialists, pharmacovigilance

experts, and medical writers) and external review teams conduct separate extensive manual review processes at each stage.

Review of TLFs by subject matter experts (physicians, kineticists, drug safety experts, medical writers) is also comprised of visual comparison and cross-checking, which is subject to reviewer fatigue and is inherently time-consuming exactly when time is critical. Subtle patterns or systemic issues may go undetected despite thorough examination.

Double programming, while providing a high level of quality assurance, also doubles resource requirements. This approach, while thorough, creates significant overhead in terms of both time and resources. Moreover, the reconciliation process between two independent programmers itself introduces delays and complexity into the development timeline and is not infallible. Even when programmers achieve a clean 'PROC COMPARE', it is not unusual for subsequent manual reviews to uncover discrepancies or additional findings requiring rework.



The current landscape of TLF development and review requires iteration and duplication throughout the study lifecycle.

IMPACT ON QUALITY AND EFFICIENCY


The challenges in current TLF development processes manifest in several critical ways that affect both the quality of outputs and the efficiency of their production. Process inefficiencies extend review cycles, perpetuate broken and redundant communications, and result in lost institutional knowledge. These issues are compounded by inconsistent implementations across projects and delayed issue resolution, which further impact the overall quality of deliverables.

Quality concerns arise from multiple sources within the current system. Manual review processes, while thorough, are both expensive and time-consuming. The high-volume, high-pressure environment inherent in clinical trial work leads to increased potential for mistakes and oversights. Poor decision-making often results from lost institutional knowledge, as valuable insights and precedents become buried in fragmented

communication channels and disconnected systems. The cumulative effect of these challenges results in quality suffering from fragmented processes and inconsistent approaches.

A BETTER APPROACH: A UNIFIED TLF DEVELOPMENT SPACE

A *unified approach to TLF development* offers transformative advantages over traditional fragmented systems. Centralized communication represents a cornerstone of this solution, providing a single point of contact where users can comment, discuss, verify, and cross-check directly on outputs. The platform enables **direct annotation** capabilities on displays, tables of contents, and mock shells, significantly reducing time spent searching for information. This centralization compresses issue adjudication timelines and creates traceable handoffs between CROs and sponsors.



Consolidate multiple information streams for simplicity, transparency, and traceability

[illegible]

Metadata management and knowledge retention capabilities provide long-term value through automated extraction of key information from TLFs, specifications, and study documents. This creates reusable metadata for future studies, leading to shortened startup times through standardized knowledge transfer. The system enhances consistency across studies while reducing redundant work through standardized approaches and shared learning.

verify
Projects
Help and Support
RV Roberta Valery

← 14.1.1.13 — 100 +

Table 14.1.1.13

Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug by System Organ Class
and Preferred Term Treatment Related - Safety Population

	Drug A (N=119)				Drug B (N=189)			
	Mild	Mod.	Sev.	Total	Mild	Mod.	Sev.	Total
Any TEAEs	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)
Infection	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)
Bronchitis viral	1 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.0%)	2 (2.0%)

N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculation.
Subjects are only counted once per event in each row.

BEACONCURE CONFIDENTIAL SDTM Creation: 08OCT2021 (00:55) Source Data: adse Table Generation: 09OCT2021

AE Table vs ADaM

Review the current alignment between **table entity** and **ADaM column** and values. Revise if necessary.

Table Entity	ADaM Column	ADaM Value(s)
Title		
Treatment-Emergent	TRTEMFL	Y
Leading to Discont...	AECN	DRUG WL...
Treatment Related	AEREL	RELATED
Safety Population	SAFFL	Y
Column/Row Headers		
Major (Treatment)	TRTA	
Minor (Severity)	AESEV	

Cancel
Save

IMPLEMENTATION CONSIDERATIONS

Change management plays a crucial role in successful implementation. Successful implementation of a unified platform requires careful attention to several details. Effective user training and support drives adoption, and encourages optimal use-cases, from statistics and programming throughout the SME review cycle.

Technical integration must ensure compatibility with existing digital systems, whether using the platform as standalone or as part of an SCE or API integration. The platform must incorporate robust data security and patient privacy controls, along with strict role-based access management systems. Compliance with ICH GCP guidelines and 21 CFR Part 11 requirements must be codified and continually ensured as product enhancements add functionality to the platform.

BENEFITS OF UNIFIED COLLABORATION

The implementation of a unified platform provides measurable benefits across multiple dimensions of TLF development and review. **Improved efficiency emerges through** the consolidation of communication methods, automated review task assignment, real-time status tracking, and rapid issue identification and resolution. This streamlined approach significantly reduces the time and resources required for routine tasks while improving overall continuity of the review process workflow.

Enhanced quality results from reduced manual review burden, consistent validation processes, and comprehensive audit trails. The unified platform enables improved decision-making through complete information availability and standardized processes. The system's ability to maintain and share knowledge across projects and teams further enhances quality outcomes.

Real-time oversight capabilities provide unprecedented visibility into the TLF development process. The platform enables continuous monitoring of deliverable status at both programmer and output levels while preserving institutional memory through comprehensive documentation. Outputs from the unified review platform provide documentation of oversight for internal management as well as regulators. This enhanced visibility also enables fast, informed decision-making and supports the **capture of key performance indicators and metrics** for ongoing process improvement.

CONCLUSION

The traditional approach to TLF development and review, while effective, has become increasingly burdensome in the face of growing clinical trial complexity. A unified platform approach offers significant advantages in efficiency, quality, and knowledge management. Through careful implementation and attention to technical and organizational detail, such platforms can transform the TLF development process from a collection of disconnected tasks into a streamlined, risk-averse and collaborative workflow that enhances both productivity and quality.

CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the authors at:

Steve Ross and Achinoam Ravet Perel
Beaconcure
867 Boylston Street, 5th Floor #1491, Boston, MA

Email:

Steve@beaconcure.com

Achinoam@beaconcure.com

Website: www.beaconcure.com

LinkedIn: <http://www.linkedin.com/company/beaconcure/>